Targeted anaplastic lymphoma kinase inhibitor

Alectinib (أليكتينيب)

Alectinib is a targeted treatment for non-small-cell lung cancer with a confirmed anaplastic lymphoma kinase alteration. It is used after removal of selected high-risk tumours or for advanced disease and requires liver, kidney, pulse, muscle, blood and lung monitoring.

This medicine is used under close medical supervision, usually by a specialist. Never start, stop or change it without your doctor.

What it is used for

  • Adjuvant treatment after complete removal of selected high-risk non-small-cell lung cancer with the confirmed target alteration
  • First-line treatment of advanced non-small-cell lung cancer with the confirmed target alteration
  • Treating advanced disease after a previous targeted medicine such as crizotinib when selected by the oncology specialist

How it is used

  • Take the capsules with food according to the oncology plan and swallow them whole without opening, crushing or dissolving them
  • If you vomit after a dose, do not replace it yourself and follow the next scheduled dose as the team directs
  • Do not stop or alter treatment without the oncology team even if symptoms improve
  • Protect skin and lips from sunlight with clothing and suitable sunscreen because sun sensitivity can increase
  • Attend requested liver, kidney, blood and muscle-enzyme tests, pulse checks and imaging follow-up

Possible side effects

  • Constipation or nausea
  • Tiredness or weakness
  • Muscle pain or raised muscle enzymes
  • Leg swelling or fluid-related weight gain
  • Anaemia or abnormal liver tests

Who should not use it

  • Allergy to alectinib or any capsule ingredient

Before and while using it

  • Jaundice, dark urine or upper-abdominal pain can indicate serious liver injury and needs urgent contact
  • New or worsening cough, fever or breathlessness can indicate lung inflammation and requires immediate interruption and assessment
  • Reduced urine, marked swelling or confusion can indicate kidney injury
  • Fainting, severe dizziness or a slow pulse needs pulse assessment and medicine review
  • Severe muscle pain, weakness or dark urine can indicate muscle injury and needs urgent testing
  • Sudden pallor, jaundice, profound tiredness or dark urine can indicate red-blood-cell breakdown

Medicine interactions

  • Medicines that slow the heart rate can add to bradycardia and require monitoring
  • It can affect medicines sensitive to selected transport proteins, such as digoxin or dabigatran, and needs pharmacist review
  • Tell the oncology team about every medicine or herb that affects liver enzymes or can injure the liver or muscles
  • Do not start a supplement or non-prescription treatment before oncology-team review

Pregnancy and breastfeeding

  • It can harm an unborn baby; tell the oncology team promptly about pregnancy or plans and use effective contraception as they direct
  • Do not breastfeed during treatment or for the safety interval in the leaflet after it stops

How to store it

  • Keep capsules in their original pack as the leaflet directs, protected from moisture and heat and out of children's reach

Get medical help straight away if

  • Your face, lips or tongue swell, or you find it hard to breathe.
  • You get a severe rash, blistering or peeling skin.
  • A side effect worries you or doesn’t go away: contact your doctor or pharmacist.

Questions about this medicine?

Talk to a doctor by video, or send your question by text.

Source: Standard international medicine references

This guide is general information and doesn’t replace advice from your doctor or pharmacist. Don’t start, stop or change a medicine without asking them, and always read the leaflet in the pack.